Literature DB >> 33792

Neuropharmacological regulation of episodic growth hormone and prolactin secretion in the rat.

J B Martin, D Durand, W Gurd, G Faille, J Audet, P Brazeau.   

Abstract

The effects on GH and PRL secretion of several pharmacological agents known to modify central neurotransmitter action were determined in unanesthetized male rats. Phenoxybenzamine, an alpha-adrenergic blocker (5 mg/kg iv), abolished episodic GH secretion and caused elevation of serum PRL levels. Propranolol, a beta-adrenergic blocker (5 mg/kg iv), had no effect on GH secretion and caused a small but significant depression in PRL levels. Parachlorophenylalanine methyl ester, an inhibitor of tryptophan hydroxylase (300-350 mg/kg ip), resulted in significant inhibition of GH pulsatile secretion and suppressed PRL levels. Methysergide hydrogen maleinate (25 mg/kg iv), a serotonin receptor antagonist, also inhibited GH secretion, but produced a transient stimulation in PRL levels. Atropine sulfate (2 mg/kg iv) caused significant suppression in GH secretion, but had no effect on PRL. Picrotoxin, a gamma-aminobutyric acid antagonist, in a subconvulsive dose of 1-3 mg/kg iv, also depressed GH episodic secretion but did not affect PRL levels. These results indicate that several neurotransmitters, i.e., norepinephrine, serotonin, acetylcholine, and gamma-aminobutyric acid, found in high concentration in the hypothalamus, influence GH and PRL secretion.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 33792     DOI: 10.1210/endo-102-1-106

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

Review 1.  The neuroendocrine approach to psychiatric disorders: a critical appraisal.

Authors:  E E Müller
Journal:  J Neural Transm Gen Sect       Date:  1990

2.  Effects of precursors on brain neurotransmitter synthesis and brain functions.

Authors:  J D Fernstrom
Journal:  Diabetologia       Date:  1981-03       Impact factor: 10.122

3.  Hypothalamic control of GH secretion: pathophysiology and clinical implications.

Authors:  H J Quabbe
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

4.  The weight gain and ultimate adiposity in cafeteria diet-induced obesity is unrelated to the central serotoninergic tonus.

Authors:  J De Schepper; X Zhou; O Louis; B Velkeniers; E Hooghe-Peters; L Vanhaelst
Journal:  Eat Weight Disord       Date:  1997-03       Impact factor: 4.652

5.  Dose-related effects of gamma-amino beta-hydroxy butyric acid (GABOB) infusion on growth hormone secretion in normal women.

Authors:  G B Melis; A M Paoletti; V Mais; N M Mastrapasqua; F Strigini; F Fruzzetti; G Guarnieri; M Gambacciani; P Fioretti
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

6.  Effect of parachlorophenylalanine, a brain serotonin depletor, on the prolactin cells of the eel pituitary.

Authors:  M Olivereau
Journal:  Cell Tissue Res       Date:  1978-07-13       Impact factor: 5.249

Review 7.  Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications.

Authors:  E E Müller; V Locatelli; S Cella; A Peñalva; A Novelli; D Cocchi
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

8.  Hormones, feeding and temperature in sheep following cerebroventricular injections of neurotransmitters and carbachol.

Authors:  P M Driver; J M Forbes; C G Scanes
Journal:  J Physiol       Date:  1979-05       Impact factor: 5.182

9.  Cholinergic and histaminergic involvement in the growth hormone releasing effect of an enkephalin analog FK 33-824 in man.

Authors:  A Peñalva; L Villanueva; F Casanueva; F Cavagnini; A Gomez-Pan; E E Müller
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  The weight gain and ultimate adiposity in cafeteria diet - induced obesity is unrelated to the central serotoninergic tonus.

Authors:  J De Schepper; X Zhou; O Louis; B Velkeniers; E Hooghe-Peters; L Vanhaelst
Journal:  Eat Weight Disord       Date:  1996-03       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.